Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Feb;39(2):295–300. doi: 10.1128/aac.39.2.295

In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184.

J C Fung-Tomc 1, B Minassian 1, E Huczko 1, B Kolek 1, D P Bonner 1, R E Kessler 1
PMCID: PMC162530  PMID: 7726485

Abstract

A new pradimicin derivative, BMS-181184, was compared with amphotericin B and fluconazole against 249 strains from 35 fungal species to determine its antifungal spectrum. Antifungal testing was performed by the broth macrodilution reference method recommended by the National Committee for Clinical Laboratory Standards (document M27-P, 1992). BMS-181184 MICs for 97% of the 167 strains of Candida spp., Cryptococcus neoformans, Torulopsis glabrata, and Rhodotorula spp. tested were < or = 8 micrograms/ml, with a majority of MICs being 2 to 8 micrograms/ml. Similarly, for Aspergillus fumigatus and 89% of the 26 dermatophytes tested BMS-181184 MICs were < or = 8 micrograms/ml. BMS-181184 was fungicidal for the yeasts, dermatophytes, and most strains of A. fumigatus, although the reduction in cell counts was less for A. fumigatus than for the yeasts. BMS-181184 was active against Sporothrix schenckii, dematiaceous fungi, and some members of the non-Aspergillus hyaline hyphomycetes. BMS-181184, however, was not fungicidal against members of the family Dematiaceae. BMS-181184 lacked activity or had poorer activity (MICs, > or = 16 micrograms/ml) against Aspergillus niger, Aspergillus flavus, Malassezia furfur, Fusarium spp., Pseudallescheria boydii, Alternaria spp., Curvularia spp., Exserohilum mcginnisii, and the zygomycetes than against yeasts. The activity of BMS-181184 was minimally (twofold or less) affected by changes in testing conditions (pH, inoculum size, temperature, the presence of serum), testing methods (agar versus broth macrodilution), or test media (RPMI 1640, yeast morphology agar, high resolution test medium). Overall, our results indicate that BMS-181184 has a broad antifungal spectrum and that it is fungicidal to yeasts and, to a lesser extent, to filamentous fungi.

Full Text

The Full Text of this article is available as a PDF (236.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartnicki-Garcia S. Cell wall chemistry, morphogenesis, and taxonomy of fungi. Annu Rev Microbiol. 1968;22:87–108. doi: 10.1146/annurev.mi.22.100168.000511. [DOI] [PubMed] [Google Scholar]
  2. CROOK E. M., JOHNSTON I. R. The qualitative analysis of the cell walls of selected species of fungi. Biochem J. 1962 May;83:325–331. doi: 10.1042/bj0830325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cameron M. L., Schell W. A., Bruch S., Bartlett J. A., Waskin H. A., Perfect J. R. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1993 Nov;37(11):2449–2453. doi: 10.1128/aac.37.11.2449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Espinel-Ingroff A., Kerkering T. M. Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi. J Clin Microbiol. 1991 Feb;29(2):393–394. doi: 10.1128/jcm.29.2.393-394.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kakushima M., Masuyoshi S., Hirano M., Shinoda M., Ohta A., Kamei H., Oki T. In vitro and in vivo antifungal activities of BMY-28864, a water-soluble pradimicin derivative. Antimicrob Agents Chemother. 1991 Nov;35(11):2185–2190. doi: 10.1128/aac.35.11.2185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Oki T., Kakushima M., Hirano M., Takahashi A., Ohta A., Masuyoshi S., Hatori M., Kamei H. In vitro and in vivo antifungal activities of BMS-181184. J Antibiot (Tokyo) 1992 Sep;45(9):1512–1517. doi: 10.7164/antibiotics.45.1512. [DOI] [PubMed] [Google Scholar]
  7. Oki T., Konishi M., Tomatsu K., Tomita K., Saitoh K., Tsunakawa M., Nishio M., Miyaki T., Kawaguchi H. Pradimicin, a novel class of potent antifungal antibiotics. J Antibiot (Tokyo) 1988 Nov;41(11):1701–1704. doi: 10.7164/antibiotics.41.1701. [DOI] [PubMed] [Google Scholar]
  8. Oki T., Tenmyo O., Hirano M., Tomatsu K., Kamei H. Pradimicins A, B and C: new antifungal antibiotics. II. In vitro and in vivo biological activities. J Antibiot (Tokyo) 1990 Jul;43(7):763–770. doi: 10.7164/antibiotics.43.763. [DOI] [PubMed] [Google Scholar]
  9. Pfaller M., Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis. 1992 Apr;11(4):287–291. doi: 10.1007/BF01962067. [DOI] [PubMed] [Google Scholar]
  10. Richardson M. D. Opportunistic and pathogenic fungi. J Antimicrob Chemother. 1991 Jul;28 (Suppl A):1–11. doi: 10.1093/jac/28.suppl_a.1. [DOI] [PubMed] [Google Scholar]
  11. Sandven P., Bjørneklett A., Maeland A. Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study Group. Antimicrob Agents Chemother. 1993 Nov;37(11):2443–2448. doi: 10.1128/aac.37.11.2443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Shadomy S. In vitro studies with 5-fluorocytosine. Appl Microbiol. 1969 Jun;17(6):871–877. doi: 10.1128/am.17.6.871-877.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Troke P. F., Marriott M. S., Richardson K., Tarbit M. H. In vitro potency and in vivo activity of azoles. Ann N Y Acad Sci. 1988;544:284–293. doi: 10.1111/j.1749-6632.1988.tb40414.x. [DOI] [PubMed] [Google Scholar]
  14. Vartivarian S. E., Anaissie E. J., Bodey G. P. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis. 1993 Nov;17 (Suppl 2):S487–S491. doi: 10.1093/clinids/17.supplement_2.s487. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES